Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
53 hedge funds and large institutions have $35.3M invested in Omega Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 8 closing their positions.
400% more call options, than puts
Call options by funds: $20K | Put options by funds: $4K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2% less funds holding
Funds holding: 54 → 53 (-1)
2.22% less ownership
Funds ownership: 87.61% → 85.39% (-2.2%)
40% less capital invested
Capital invested by funds: $59M → $35.3M (-$23.7M)
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$160K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$122K |
| 3 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$13.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12K |
| 5 |
C
Certuity
North Palm Beach,
Florida
|
+$4.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$455K |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$423K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$137K |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
-$89.7K |
| 5 |
Two Sigma Investments
New York
|
-$59.1K |
OMGA Hedge Fund Activity: Q4 2024 in Review
53 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q4 2024, worth a combined $35.3M — down 40% from $59M a quarter earlier.
Fund positioning in OMGA was balanced in Q4 2024: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 15 trimmed.
The largest buyer was UBS Group, adding an estimated $160K. The largest seller was Renaissance Technologies, cutting an estimated $455K.
- 53 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q4 2024, down from 54 in Q3 2024.
- Funds reported $35.3M of Omega Therapeutics, Inc. Common Stock stock for Q4 2024, down 40% quarter-over-quarter.
- 8 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q4 2024 and 8 closed out, a net change of 0 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q4 2024 was UBS Group, an estimated $160K added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q4 2024 was Renaissance Technologies, an estimated $455K sold.
Based on aggregated 13F filings for Q4 2024.